EI
BPMC

EAM Investors’s Blueprint Medicines BPMC Stock Holding History

EAM Investors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-44,149
Closed -$4.07M – 252
2023
Q4 		$4.07M Buy
+44,149
New +$2.86M 0.72% 28
2021
Q1 		– Sell
-19,813
Closed -$2.22M – 347
2020
Q4 		$2.22M Sell
19,813
-703
-3% -$74.1K 0.36% 88
2020
Q3 		$1.9M Buy
+20,516
New +$1.58M 0.45% 66
2018
Q2 		– Sell
-22,862
Closed -$2.1M – 297
2018
Q1 		$2.1M Sell
22,862
-4,203
-16% -$362K 0.35% 138
2017
Q4 		$2.04M Buy
+27,065
New +$1.9M 0.37% 130

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's BPMC Position: Q1 2024 in Review

EAM Investors sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 44,149 shares — an estimated $4.07M sold.

EAM Investors first reported a position in BPMC in Q4 2017 and held it in 5 quarters. The position peaked at $4.07M in Q4 2023. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • EAM Investors reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 44,149 Blueprint Medicines shares in Q1 2024, an estimated $4.07M.
  • EAM Investors first reported a position in Blueprint Medicines in Q4 2017 and held it in 5 quarters.
  • EAM Investors's Blueprint Medicines position peaked at $4.07M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.